Birchview Capital
Latest statistics and disclosures from Birchview Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are KLAC, BMY, LRCX, SLDB, NTLA, and represent 46.51% of Birchview Capital's stock portfolio.
- Added to shares of these 10 stocks: KLAC (+$48M), NKTR, ABVX, VIR, HALO, BIOA, NVO, ADAG, DFTX, CORT.
- Started 14 new stock positions in FDMT, VIR, ADAG, URGN, IVVD, NVO, SVRA, CAPR, DFTX, ALT. SLN, ABVX, CAMP, BIOA.
- Reduced shares in these 10 stocks: CMPS, GPCR, OCUL, QURE, NVCR, Engene Holdings, PHAT, RARE, Kalvista Pharmaceuticals, STOK.
- Sold out of its positions in Apellis Pharmaceuticals, APGE, RCUS, Engene Holdings, IDYA, Kalvista Pharmaceuticals, Outset Med, PHR, RGNX, RCKT. RARE, VSTM, VRDN, ZNTL, NVCR.
- Birchview Capital was a net buyer of stock by $38M.
- Birchview Capital has $214M in assets under management (AUM), dropping by 21.58%.
- Central Index Key (CIK): 0001618205
Tip: Access up to 7 years of quarterly data
Positions held by Birchview Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Birchview Capital
Birchview Capital holds 72 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Kla Corporation Com New (KLAC) | 25.2 | $54M | +797% | 179k | 301.71 |
|
| Bristol Myers Squibb (BMY) | 8.0 | $17M | -2% | 297k | 57.62 |
|
| Lam Research Corporation Com New (LRCX) | 7.1 | $15M | -2% | 35k | 433.33 |
|
| Solid Biosciences Com New (SLDB) | 3.1 | $6.7M | +6% | 666k | 9.99 |
|
| Intellia Therapeutics (NTLA) | 3.1 | $6.5M | -13% | 386k | 16.92 |
|
| Biodesix | 3.0 | $6.5M | 287k | 22.55 |
|
|
| Stoke Therapeutics (STOK) | 2.7 | $5.8M | -15% | 178k | 32.72 |
|
| Encana Corporation (OVV) | 2.7 | $5.7M | 108k | 52.65 |
|
|
| Nektar Therapeutics (NKTR) | 2.6 | $5.7M | +161% | 81k | 69.81 |
|
| Corcept Therapeutics Incorporated (CORT) | 2.3 | $5.0M | +21% | 57k | 86.95 |
|
| Neurocrine Biosciences (NBIX) | 2.1 | $4.6M | 27k | 168.53 |
|
|
| Prothena Corp SHS (PRTA) | 2.1 | $4.4M | 449k | 9.79 |
|
|
| ACADIA Pharmaceuticals (ACAD) | 2.0 | $4.3M | 171k | 25.30 |
|
|
| Protagonist Therapeutics (PTGX) | 2.0 | $4.3M | 35k | 122.58 |
|
|
| Compass Therapeutics (CMPX) | 1.7 | $3.7M | +14% | 1.7M | 2.19 |
|
| Relmada Therapeutics (RLMD) | 1.3 | $2.8M | 408k | 6.92 |
|
|
| Alkermes SHS (ALKS) | 1.2 | $2.6M | 50k | 52.40 |
|
|
| Halozyme Therapeutics (HALO) | 1.2 | $2.6M | +229% | 33k | 78.27 |
|
| Celldex Therapeutics Com New (CLDX) | 1.2 | $2.6M | 70k | 37.21 |
|
|
| Cytokinetics (CYTK) | 1.2 | $2.6M | 30k | 85.19 |
|
|
| Olema Pharmaceuticals (OLMA) | 1.2 | $2.5M | -9% | 199k | 12.51 |
|
| Vera Therapeutics Cl A (VERA) | 1.2 | $2.5M | +31% | 58k | 42.91 |
|
| United Therapeutics Corporation (UTHR) | 1.1 | $2.4M | 4.5k | 541.83 |
|
|
| Zenas Biopharma (ZBIO) | 1.1 | $2.4M | +33% | 94k | 25.38 |
|
| Uniqure Nv SHS (QURE) | 1.1 | $2.3M | -49% | 51k | 46.06 |
|
| Pacific Biosciences of California (PACB) | 1.1 | $2.3M | -10% | 1.4M | 1.68 |
|
| Abivax Sa Sponsored Ads (ABVX) | 1.1 | $2.3M | NEW | 17k | 133.26 |
|
| Vir Biotechnology (VIR) | 1.0 | $2.2M | NEW | 220k | 10.19 |
|
| Biogen Idec (BIIB) | 0.9 | $1.9M | +80% | 9.0k | 216.06 |
|
| EQT Corporation (EQT) | 0.9 | $1.8M | 35k | 53.17 |
|
|
| Bioage Labs (BIOA) | 0.8 | $1.7M | NEW | 69k | 24.51 |
|
| Travere Therapeutics (TVTX) | 0.8 | $1.6M | 29k | 56.81 |
|
|
| Quidel Corporation | 0.7 | $1.6M | +8% | 89k | 17.52 |
|
| Axsome Therapeutics (AXSM) | 0.7 | $1.5M | 6.0k | 244.77 |
|
|
| Foghorn Therapeutics (FHTX) | 0.6 | $1.4M | 282k | 4.88 |
|
|
| Bicycle Therapeutics Sponsored Ads (BCYC) | 0.6 | $1.3M | -32% | 314k | 4.24 |
|
| Structure Therapeutics Spons Adr (GPCR) | 0.6 | $1.3M | -76% | 24k | 53.67 |
|
| Xenon Pharmaceuticals (XENE) | 0.6 | $1.3M | 21k | 60.36 |
|
|
| Novo Nordisk A/s Adr (NVO) | 0.5 | $1.2M | NEW | 24k | 47.94 |
|
| Freeport-mcmoran Cl-b CL-B (FCX) | 0.5 | $1.1M | 18k | 62.89 |
|
|
| Immunome (IMNM) | 0.5 | $1.1M | 50k | 21.19 |
|
|
| Pharvaris N V (PHVS) | 0.5 | $1.0M | 30k | 34.58 |
|
|
| Harrow Health (HROW) | 0.5 | $1.0M | 24k | 42.47 |
|
|
| Adagene Ads (ADAG) | 0.5 | $1.0M | NEW | 240k | 4.20 |
|
| Definium Therapeutics Com Shs (DFTX) | 0.4 | $941k | NEW | 20k | 47.04 |
|
| Silence Therapeutics Ads (SLN) | 0.4 | $782k | NEW | 71k | 10.98 |
|
| Bridgebio Pharma (BBIO) | 0.3 | $651k | 8.7k | 74.48 |
|
|
| 4d Molecular Therapeutics In (FDMT) | 0.3 | $645k | NEW | 49k | 13.30 |
|
| Urogen Pharma (URGN) | 0.3 | $607k | NEW | 17k | 36.80 |
|
| Phathom Pharmaceuticals (PHAT) | 0.3 | $597k | -71% | 55k | 10.85 |
|
| Camp4 Therapeutics Corp (CAMP) | 0.2 | $524k | NEW | 120k | 4.37 |
|
| Savara (SVRA) | 0.2 | $493k | NEW | 80k | 6.16 |
|
| Candel Therapeutics (CADL) | 0.2 | $492k | -20% | 48k | 10.30 |
|
| Altimmune Com New (ALT) | 0.2 | $464k | NEW | 153k | 3.04 |
|
| Compass Pathways Sponsored Ads (CMPS) | 0.2 | $425k | -92% | 30k | 14.15 |
|
| Karyopharm Therapeutics | 0.2 | $420k | -48% | 43k | 9.77 |
|
| Cullinan Oncology (CGEM) | 0.2 | $364k | 20k | 18.21 |
|
|
| Trinity Cap (TRIN) | 0.2 | $358k | 20k | 17.89 |
|
|
| Capricor Therapeutics Com New (CAPR) | 0.2 | $346k | NEW | 14k | 24.08 |
|
| Castle Biosciences (CSTL) | 0.1 | $310k | 13k | 23.85 |
|
|
| Adagio Therapeutics (IVVD) | 0.1 | $299k | NEW | 342k | 0.87 |
|
| Acasti Pharma (GRCE) | 0.1 | $272k | +140% | 120k | 2.27 |
|
| Kayne Anderson Bdc Com Shs (KBDC) | 0.1 | $271k | 20k | 13.53 |
|
|
| Voyager Therapeutics (VYGR) | 0.1 | $263k | 75k | 3.50 |
|
|
| Pulmonx Corp (LUNG) | 0.1 | $261k | -19% | 201k | 1.30 |
|
| Ocular Therapeutix (OCUL) | 0.1 | $203k | -93% | 21k | 9.82 |
|
| Kyntra Bio Com New (KYNB) | 0.1 | $170k | 23k | 7.55 |
|
|
| Aziyo Biologics (ELUT) | 0.1 | $162k | 165k | 0.98 |
|
|
| Quoin Pharmaceuticals Sponsored Ads (QNRX) | 0.0 | $97k | 20k | 4.84 |
|
|
| Lipocine Com New (LPCN) | 0.0 | $43k | -85% | 17k | 2.56 |
|
| Docgo (DCGO) | 0.0 | $20k | 39k | 0.52 |
|
|
| Gossamer Bio (GOSS) | 0.0 | $3.0k | 18k | 0.16 |
|
Past Filings by Birchview Capital
SEC 13F filings are viewable for Birchview Capital going back to 2014
- Birchview Capital 2026 Q2 filed Aug. 14, 2026
- Birchview Capital 2026 Q1 filed May 15, 2026
- Birchview Capital 2025 Q4 filed Feb. 13, 2026
- Birchview Capital 2025 Q3 filed Nov. 13, 2025
- Birchview Capital 2025 Q2 filed Aug. 14, 2025
- Birchview Capital 2023 Q3 amended filed June 30, 2025
- Birchview Capital 2023 Q4 amended filed June 30, 2025
- Birchview Capital 2024 Q1 amended filed June 30, 2025
- Birchview Capital 2024 Q2 amended filed June 30, 2025
- Birchview Capital 2024 Q3 amended filed June 30, 2025
- Birchview Capital 2024 Q4 amended filed June 30, 2025
- Birchview Capital 2025 Q1 filed May 15, 2025
- Birchview Capital 2024 Q4 filed Feb. 14, 2025
- Birchview Capital 2024 Q3 filed Nov. 14, 2024
- Birchview Capital 2024 Q2 filed Aug. 13, 2024
- Birchview Capital 2024 Q1 filed May 14, 2024